Cells Weekly – September 25, 2016

by Alexey Bersenev on September 26, 2016 · 0 comments

in notes

Cells Weekly is a digest of the most interesting news and events in stem cell research, cell therapy and regenerative medicine. Cells Weekly is posted every Sunday night!

Announcement 1
Annual 2016 Ogawa-Yamanaka Stem Cell Prize award ceremony will take place on Wednesday, September 28 at 11am PST at the Gladstone Institutes (San Francisco, California). If you will not be in San Francisco, you can watch live-stream of the event online.
The Ogawa-Yamanaka Stem Cell Prize recognizes individuals whose original translational research has advanced cellular reprogramming technology for regenerative medicine. Recipients receive an unrestricted prize of $150,000 USD

Announcement 2
All “cell reprogramming crowd” gathered for 3 days in Berkley, California for Cell Symposia “10 Years of iPS“. There is a quite good activity on twitter, so you can follow it live via hashtag #csstemcells16.

1. FDA public hearing on regulation of cell therapy
Last week FDA organized first public hearing in the history of cell therapy field. I did not attend, but was watching it via live webcast. Here is my coverage:

The reason for the hearing was unexpectedly high number of controversial comments about 4 guidances that FDA released in 2014-2015. These guidances are aimed to clarify FDA’s current thinking on regulatory classification of Human Cell Tissue Products (HCT/P) and included definitions of “same surgical procedure“, “homologous use“, “minimal manipulation” and “adipose tissue-derived products“. The latest guidance was released almost a year ago, so it was long overdue to have this public hearing. Unusual public participation and controversial comments made FDA to reschedule this event from April to September and split it for 2 days. You can watch recorded webcast here and here.

I’d like to invite you all to discuss it with me!

2. CRISPR gene editing of normal human embryos
NPR released the news this week about the first attempt to use CRIPS gene editing on healthy human embryos in Sweden:

The step by the developmental biologist Fredrik Lanner makes him the first researcher known to attempt to modify the genes of healthy human embryos. That has long been considered taboo because of safety and ethical concerns.

Lanner, however, says he is initially planning only to study the modified embryos for the first seven days of their growth and would never let them develop past 14 days. The potential benefits could be enormous, he argues.
“Having children is one of the major drives for a lot of people,” Lanner says. “For people who do struggle with this, it can tend to become an extremely important part of your life.”

3. Results of 2 cellular immunotherapy trials
I’d like to bring your attention to two recently published clinical studies in cancer cellular immunotherapy field. First, defined composition of CAR T-cell therapy of non-Hodgkin’s lymphoma by Fred Hutchinson Cancer Center. Important conclusion here is that good efficacy and cell persistence was observed after addition of fludarabine in conditioning regimen. Sorting of CD8+ cell subsets (bulk versus central memory) was useless.
Second study is small safety trial, which assessed so-called memory-like NK cells in acute myeloid leukemia (AML). Besides safety endpoints, 4/9 patient went to complete remission – very good preliminary result for NK cell field.

4. The history of the first bone marrow transplant
Jovana Drinjakovic of the Signals blog wrote a wonderful story about the first bone marrow transplant cases in adults:

It was a failed transplant that saved his life. In 1958, Radojko Maksic became the first person to receive a bone marrow graft from a stranger, after he was accidentally exposed to a lethal dose of radiation in Belgrade, in what was then Yugoslavia. He still lives in Belgrade, almost 60 years after the procedure.

Highly recommended to read whole piece!

5. Assessment of young blood plasma in Alzheimer Disease model
Stanford’s neuroscientist Tony Wyss-Coray, who studied effects of “young blood” on brain rejuvenation, has started company (Alkahest) and clinical trial 2 years ago. However, preclinical data for this particular trial were not released. Now, Wyss-Coray’s group published a rationale study for Alzheimer Disease trial:

Aged mutant amyloid precursor protein mice with established disease showed a near complete restoration in levels of synaptic and neuronal proteins after exposure to young blood in parabiosis (synaptophysin P = .02; calbindin P = .02) or following intravenous plasma administration (synaptophysin P < .001; calbindin P = .14).

6. Testing of pancreatic organoids in transplantation model
Organoids field is moving to in vivo models. It is important test for the safety, engraftment and function of organoids. Researchers from Germany created human pancreatic organoids from pluripotent stem cells and tested them in xenomodel:

Upon orthotopic transplantation into immunodeficient mice, these organoids form normal pancreatic ducts and acinar tissue resembling fetal human pancreas without evidence of tumour formation or transformation. Finally, we implemented this unique phenotyping tool as a model to study the pancreatic facets of cystic fibrosis (CF). For the first time, we provide evidence that in vitro, but also in our xenograft transplantation assay, pancreatic commitment occurs generally unhindered in CF.

{ 0 comments }

Cells Weekly – September 5, 2016

by Alexey Bersenev on September 5, 2016 · 0 comments

in notes

Cells Weekly is a digest of the most interesting news and events in stem cell research, cell therapy and regenerative medicine. Cells Weekly is posted every Sunday night!

1. Amniotic Therapies versus FDA
US-based manufacturer of amniotic tissue-derived products for regenerative medicine Amniotic Therapies has received warning letter from FDA. This letter is warning company for many reasons, but two major are the following: (1) misbranding and marketing their product as 361 HCT/P, which they are drugs and must be regulated as 351 drugs and (2) contamination of one lot with mycoplasma and 4 adverse events as a consequence. The letter was issued on August 17 and it gives only 15 days for response. Apparently, company response was not satisfactory and FDA may order to cease operation (I was not able to find documented proof of it). The company responded by lawsuit against FDA (“to block FDA’s order”) – you can read details here. Few hours after filing lawsuit, Texas federal judge barred FDA from “shuttering” of company “over perceived sanitary problems”. The company said that contamination was doctor’s fault, who administered the product to patient without reading package insert.

2. Update on Macchiarini’s investigation
Karolinska University Hospital, which investigated ethical research misconduct by tissue engineering pioneer Paolo Macchiarini, has released report this week. Hospital, basically admitted that Macchiarini’s hire should not even happen in the first place:

“Much went wrong in connection with Macchiarini’s transplants of synthetic trachea,” said Asplund in a statement when he presented the results of the inquiry on Wednesday.
“Macchiarini should not even have been employed at the hospital. There were shortcomings in how the decisions about the transplants were made and how they acted on existing laws. The hospital has a big task ahead to ensure patient safety and trust.”

Some leadership positions were suspended. Read more details on For Better Science blog:

The Asplund report found gross violations of medical ethics, patient right, even recruitment processes when analysing the history of the scandal around the Italian surgeon. Unlike repeatedly declared by both KI and KS, Macchiarini’s trachea transplants were not medical emergencies and not compassionate care cases…

Also read some details from Nature News:

The affair has damaged trust in clinical research in Sweden, says the report, but the hospital is already taking steps to improve things. For example, it has prepared internal guidelines for experimental clinical methods and for how to deal with whistle-blowers.
Acting KI vice-chancellor Karin Dahlman-Wright said in a statement that “it would be extremely regrettable if the Karolinska Institutet had exerted any kind of pressure” in hiring Macchiarini. The KI will publish its own report on the case on 5 September. Macchiarini and his lawyer declined to comment on the latest report.

3. Credit for discovery of medical optogenetics
Anna Vlasists by STAT News wrote a great piece about development of medical optogenetics field and its pioneers. The major theme of her article is who should be credited for key discoveries and pioneering the field. We all know that Karl Deisseroth and Ed Boyden are widely credited as pioneers, but another researcher – Zhuo-Hua Pan, conducted key experiments first. Pan just got “less lucky” with his publication (it stuck in reviews for 2 years), so, Deisseroth and Boyden published first:

So Pan and Dizhoor wrote a paper about their work and submitted it to Nature on November 25, 2004, according to the submission letter Pan shared with STAT. The editors at Nature suggested they send it on to a more specialized journal called Nature Neuroscience, which rejected it. Early the next year, Pan sent the paper to the Journal of Neuroscience, where it was reviewed but then again rejected.

Why didn’t Pan’s paper get published first? He may never know the answer. After Boyden’s paper came out, Pan wrote to the editor at Nature Neuroscience asking how they could have rejected his paper but published Boyden’s.
In her response, the editor replied that while the papers were similar, Boyden et al. presented theirs as a new technology rather than as a scientific finding. Pan’s paper, it seemed, was too narrow, only focusing on using channelrhodopsin to restore vision, while Boyden’s paper took the broad view of thinking of channelrhodopsin as a tool for neuroscience in general.

Anna Vlasists discusses the problem with delaying of publications and crediting scientists for discoveries. We can draws parallels with CRISPR patents/ crediting war, since both technologies have a “Nobel Prize potential”.

As for the invention itself, some scientists say Pan may not have had the big, award-worthy vision that Deisseroth and Boyden had. Stefan Herlitze, one of the others who was scooped for the first publication about channelrhodopsin in neurons, said, “Of course I have to say, Deisseroth and Boyden, they really developed the field further.”
Boyden echoed this. “Karl and I were very interested in the general question of how to control cell types in the brain,” he said. “In recent years, we worked to push these molecules to their logical limits.”
So maybe it doesn’t matter who invented optogenetics, just who has stretched science’s boundaries the furthest.
Asked whether he deserves the recognition that Boyden and Deisseroth have enjoyed, Pan declined to answer. He later told STAT that Deisseroth “also did a very excellent job, no doubt. But he’s also very lucky because if our paper was ahead of him, the story would be different. We would have gotten more credit.”

Highly recommended to read!

4. Role of hematopoietic stem cells in steady state hematopoiesis
It is remain not very clear if all blood cell types are developed from one hematopoietic stem cell (HSC) in normal hematopoiesis, because of limitations of conventional transplantation models. In these models, host bone marrow severely damaged by lethal irradiation and donor cells can skew hematopoietic repopulation in toxic marrow environment. Recent studies, challenged significant contribution of HSCs in immune reconstitution. Results of very recent study, which used more appropriate model of steady state hematopoiesis, were published in Immunity.

Inducible genetic labeling showed that transgene-expressing HSCs gave rise to other phenotypic HSCs, confirming their top position in the differentiation hierarchy. The labeled HSCs rapidly contributed to committed progenitors of all lineages and to mature myeloid cells and lymphocytes, but not to B-1a cells or tissue macrophages.

5. Accelerated aging of immune system after hematopoietic stem cell transplantation
Researchers demonstrated that hematopoietic stem cell transplantation in patients with hematological malignancies significantly accelerates aging of immune system. They measured aging marker p16 on blood cells before and after of chemotherapy with hematopoietic stem cell transplantation. Turns out that expression of this aging marker on T-cells was significantly higher after transplant. Effect was especially profound in autologous transplant and in patient with more cycles of chemotherapy. The senior author said:

“Many oncologists would not be surprised by the finding that stem cell transplant accelerates aspects of aging,” said the study’s senior author Norman Sharpless, MD, director of UNC Lineberger and the Wellcome Distinguished Professor in Cancer Research. “We know that years after a curative transplant, stem cell transplant survivors are at increased risk for blood problems that can occur with aging, such as reduced immunity, increased risk for bone marrow failure, and increased risk of blood cancers. What is important about this work, however, is that it allows us to quantify the effect of stem cell transplant on molecular age.”

6. Cancer stem cell database
Overview of new public database for identification of characterization of cancer stem cell is described this week in Stem Cells TM.

Herein, we describe the Cancer Stem Cells Therapeutic Target Database (CSCTT), the first online database to provide a rich bioinformatics resource for the display, search, and analysis of structure, function, and related annotation for therapeutic targets of cancer stem cells. CSCTT contains 135 proteins that are potential targets of CSCs, with validated experimental evidence manually curated from existing literatures.

Link to database.

***********************
bonus:

{ 0 comments }

Clinical Cell Processing News – part 4, 2016

by Alexey Bersenev on August 31, 2016 · 0 comments

in clinical lab

Clinical Cell Processing News is a series about new protocols, products and techniques for clinical-grade cell processing and manufacturing. Cell processing devices, cultureware, bioreactors, GMP-grade reagents, cell separation techniques. This series is posted every 2 months.

FEATURED:
Identification and validation of multiple cell surface markers of adipose-derived MSCs for GMP manufacturing (Stem Cell Res Ther) FREE

Our study establishes that clinical-grade AMSCs expanded in hPL represent a homogeneous cell culture population according to classical markers,. Additionally, we validated new biomarkers for further AMSC characterization that may provide novel information guiding the development of new release criteria.

1. A rapid sonication based method for preparation of stromal vascular fraction (Bioimpacts) FREE

The current protocol based on the sonication-mediated cavitation is a rapid, safe and cost-effective method, which is proposed for isolation of SVF and of course ADSCs cultures in a large scale for the clinical trials or therapeutic purposes.

2. Validation of Quantum Cell Expansion system for clinical-scale production of human periosteum derived stem cells (Cytotherapy):

The data show that the hollow fiber bioreactor is capable of robustly expanding autologous hPDCs on a clinical scale (yield between 316 million and 444 million cells starting from 20 million after ± 8 days of culture) while maintaining their in vitro quality attributes compared with the standard flask-based culture.

3. Protocol for GMP manufacturing of ADV-specific T-cells using G-Rex flasks (Cytotherapy):

Thirty-eight of 40 products (95%) met all release criteria. Median purity of the cell product was 88.3% CD3+ cells with a median yield of 2.9 × 107 CD3+ cells. Potency analyses showed a median ADV-specific interferon (IFN)γ response of 5.9% of CD3+ and 2345 IFNγ spot-forming cells/million.

4. Development of potency assay for immunomodulatory function of MSC (Immunol Lett):

The aims of this study were to develop an optimised rapid turnaround, flow cytometry-based whole-blood assay to monitor MSC potency and to validate its application to MSC immunomodulation. A protocol for short-term LPS stimulation of anti-coagulated whole blood samples followed by combined surface CD45/CD14 and intracellular TNF-α staining was initially developed for analysis on a 4 colour desktop cytometer.

5. A novel method for adipose-derived cell isolation with increased cell yield (Plast Reconstr Surg):

We have developed a protocol that maximizes the yield of ASCs derived from lipoaspirate. We demonstrate that NM-ASCs have increased osteogenic and adipogenic potential in vitro and are non-inferior to CM-ASCs in terms of their ability to generate bone and fat in vivo.

6. Feasibility of manufactturing CAR-CD171 cells for cell therapy of neuroblastoma (Clin Cancer Res)

Manufacturing of lentivirally transduced CD4+ and CD8+ CE7-CAR T cell products under GMP was successful in 4 out of 5 consecutively enrolled neuroblastoma patients in a phase I study. All four CE7-CAR T cell products demonstrated in vitro and in vivo anti-tumor activity. Conclusion: Our preclinical assessment of the CE7 epitope on CD171 supports its utility and safety as a CAR T cell target for neuroblastoma immunotherapy.

7. Clinical-scale production of T-regs from ALS patients (Cytotherapy)

In vitro expansion of Tregs for 4 weeks in the presence of GMP-grade anti-CD3/CD28 beads, interleukin (IL)-2 and rapamcyin resulted in a 25- to 200-fold increase in their number and restored their immunoregulatory activity. Collectively, our data facilitate and support the implementation of clinical trials of adoptive therapy with ex vivo expanded and highly suppressive Tregs in patients with ALS.

8. Validation of MyStem EVO kit for cell purification of the fluid portion of lipospirates (Plast Reconstr Surg):

The alternative procedures enabled comparable yields; the kit rapidly isolated lipoaspirate fluid comprising a homogenous cell population with adipose stem cell immunophenotype, bilineage potential, and efficient osteoinductive and angioinductive features.

9. Review: Scalable microcarrier-based manufacturing of mesenchymal stem/stromal cells (J Biotechnol)

{ 0 comments }

Cells Weekly – August 28, 2016

by Alexey Bersenev on August 29, 2016 · 0 comments

in notes

Cells Weekly is a digest of the most interesting news and events in stem cell research, cell therapy and regenerative medicine. Cells Weekly is posted every Sunday night!

1. Stem cell blog carnival
Canadian the Signals blog hosted for the first time hosted stem cell blog carnival:

Think of a blog carnival as a single venue hosting a variety of entertainment. In this case, the “entertainment” are posts from influential bloggers across the stem cell research community all blogging on the same topic. Visit Signals next Thursday to gain access to all of these perspectives. As you jump from post to post, just as you would between booths at a carnival, it’s a chance to absorb a wide range of opinions and viewpoints from scientists and science communications experts. I’ve read a few of the blogs already and each one is interesting and different – as unique as their authors. You’re in for a real treat.

The theme of the first carnival was 10 years of iPS cell discovery.
The Signals did a great job in promotion of the first carnival and gathering posts together. 11 posts from 7 blogs participates in carnival! Remarkable event for the stem cell social media! I’d highly encourage you to read all posts, give feedback and participate in next carnivals!

2. Commercialization of cell therapy products in Europe
A week ago I wrote a post about failing commercialization of approved cell/ gene therapy products in Europe:

3/4 (75%) purely cell-based ATMPs or 3/7 (43%) of all approved ATMPs were withdrawn in the last 3 years! We can exclude Zalmoxis, which yet to be approved, and statistics will be even worse. We can also exclude Glybera, which was administered only once in 3 post-approval years and considered as commercial flop, and statistics will be much worse. So, is this the solid case of failed ATMPs commercialization? Yes, at this point it is.

I’d like to invite you for discussion!

3. Role of tissue resident stem cells in cancer risk
Very important study for understanding of the cancer-initiating cells and their relationships with normal tissue stem cells was published this week in Cell. Researchers used very elegant models to demonstrate that cancer risk depends on function of resident adult stem cells:

We show that tumor incidence is determined by the life-long generative capacity of mutated cells. This relationship held true in the presence of multiple genotypes and regardless of developmental stage, strongly supporting the notion that stem cells dictate organ cancer risk. Using the liver as a model system, we further show that damage-induced activation of stem cell function markedly increases cancer risk.

4. New level of tissue clearing – see through the body
Researchers from University of Munich brought tissue clearing techniques to the new level – fully transparent body. New modified method called uDiSCO:

We developed ‘ultimate DISCO’ (uDISCO) clearing to overcome these limitations in volumetric imaging. uDISCO preserves fluorescent proteins over months and renders intact organs and rodent bodies transparent while reducing their size up to 65%. We used uDISCO to image neuronal connections and vasculature from head to toe over 7 cm and to perform unbiased screening of transplanted stem cells within the entire body of adult mice.

Images from the paper are amazing!

5. Patient to sue stem cell clinic
Patient, who underwent unproven stem cell therapy, was not satisfied with result and filed lawsuit against the clinic:

Rivero’s suit says the Lung Institute violated Florida’s Deceptive and Unfair Trade Practices Act by duping clients into believing stem-cell therapy worked despite the absence of credible medical evidence.
“It’s one thing for folks that have an incurable disease to try experimental treatments,” said Rivero’s attorney, Ben Vinson Jr. of Tampa. “But it’s another when the person offering the treatment knows it doesn’t work.”

Totally opposite story, related to Lung Institute, went out in mass media in almost the same day with lawsuit story.

6. New method for expansion of nephrogenic progenitors
Belmonte’s group from Salk Institute described a new methodology for long-term expansion of human nephrogenic progenitor cells and its organization in kidney nephrons:

Here, we show that with appropriate 3D culture conditions, it is possible to support long-term expansion of primary mouse and human fetal NPCs as well as NPCs derived from human induced pluripotent stem cells (iPSCs). Expanded NPCs maintain genomic stability, molecular homogeneity, and nephrogenic potential in vitro, ex vivo, and in vivo.

The method looks promising and could be potentially scalable for clinical applications.

7. On toxicity of CAR T-cell therapy
Due to recent CAR T-cell therapy clinical trial temporary suspension, the topic of related toxicity all over the place. STAT news this week posted a piece, where called CAR T-cell therapy as “terrifying”:

One of the hallmarks of CAR-T: It has to nearly kill you if it’s going to save you

This is misleading statement, of course, but article is worth reading.
Yet another interesting piece on the same topic was posted on the Pharmaceutical Journal site:

Competition between the various academic institutions is also fierce. Fred Hutchinson Cancer Research Center, University of Pennsylvania and Memorial Sloan Kettering Cancer Center, among others, have welcomed investment from industry and philanthropy. The University of Pennsylvania now boasts the largest immuno-oncology group working on CAR-T, with 300 researchers (three years ago there were only 40 researchers). And with grant money now easier to secure, new research groups have sprung up. Reflecting on the sudden popularity of the field, Brentjens says: “I guess for the people who started out this race there wants to be some sense that their contribution is acknowledged. I would say that the field is getting very crowded now.”

8. Fresh reviews:
Adult Stem Cell Therapy and Heart Failure, 2000 to 2016 (JAMA Cardiol)
Meta-analysis: Neural Stem Cells therapy for experimental ischemia stroke in preclinical studies (Sci Rep)

{ 0 comments }

Cells Weekly – August 21, 2016

by Alexey Bersenev August 22, 2016 notes

Cells Weekly is a digest of the most interesting news and events in stem cell research, cell therapy and regenerative medicine. Cells Weekly is posted every Sunday night! 1. “Money back guarantee” for cell-gene therapy drug High prices for marketed cell/ gene therapy products is a hot and controversial topic. For example, approved gene therapy […]

1 comment Read the full article →

Cells Weekly – August 7, 2016

by Alexey Bersenev August 8, 2016 notes

Cells Weekly is a digest of the most interesting news and events in stem cell research, cell therapy and regenerative medicine. Cells Weekly is posted every Sunday night! 1. Anti-aging trial uses young blood New clinical trial (sanctioned by FDA!), launched by company Ambrosia has captured a lot of attention this week. It uses “young […]

0 comments Read the full article →

Will Prodigy change everything?

by Alexey Bersenev August 6, 2016 cell product

In the last decade advanced cell therapies are becoming highly commercialized. Industry developers, in general, favor so-called centralized model of cell product manufacturing/ delivery. In centralized model, one big manufacturing plant produces and delivers many many (thousands) products within a country or internationally. In the last few years, Biotech and cell therapy companies (Novartis, Kite […]

6 comments Read the full article →

Cells Weekly – July 31, 2016

by Alexey Bersenev July 31, 2016 notes

Cells Weekly is a digest of the most interesting news and events in stem cell research, cell therapy and regenerative medicine. Cells Weekly is posted every Sunday night! 1. Dispelling the myth of premature aging of cloned animals Very important study, proving that cloned animals don’t have serious health problems with age, was published this […]

0 comments Read the full article →

Cells Weekly – July 24, 2016

by Alexey Bersenev July 25, 2016 notes

Cells Weekly is a digest of the most interesting news and events in stem cell research, cell therapy and regenerative medicine. Cells Weekly is posted every Sunday night! 1. CRISPR clinical trial in China Nature reported this week about the world’s first clinical trial, involved CRISPR gene edited cells. The trial is planning to start […]

1 comment Read the full article →

Cells Weekly – July 17, 2016

by Alexey Bersenev July 18, 2016 notes

Cells Weekly is a digest of the most interesting news and events in stem cell research, cell therapy and regenerative medicine. Cells Weekly is posted every Sunday night! 1. Resolving Betatrophin controversy I’ve followed controversy around pacreatic beta-cells growth factor betatrophin, described by Harvard’s Doug Melton (read here and here). This week, “controversy resolution” report […]

0 comments Read the full article →